Dr Christopher Jensen

Chief Operating Officer, Triple Helix Science

Taking gene and cell therapy global without lowering the standard of care

Roughly monthly. Unsubscribe any time.

Contact for media →

Featured inFrontiers in PharmacologyFrontiers in Drug Delivery

What Christopher writes about

Dr Christopher Jensen writes about what it takes to deliver gene and cell therapy safely in the real world: clinical protocols, quality systems and the logistics of matching manufacturing to each patient's treatment. He covers how nations building new healthcare systems can hold a single standard of care across sites and regulators, and his group's research into immune system restoration.

Christopher's newsletter, The Precision Economy, comes out roughly monthly, tracking how precision medicine moves from elite centres to the nations ready to build around it.

Physician and surgeon in the NHS since 2009, and a police surgeon in London since 2011.

Newsletters

The Precision EconomyChristopher's newsletter

First issue coming soon

Comes out roughly monthly, tracking how precision medicine moves from elite centres to the nations ready to build around it.

Sign up now to get the first issue. Unsubscribe any time.

Media reaction

Preventative care and emerging health systems

"Healthcare is shifting from treating illness to preventing it, and that will transform patient outcomes and health systems alike. The biggest opportunity lies with governments in emerging economies building from scratch. Free of legacy infrastructure, they can deliver next-generation care at scale or become international hubs for treatment."
Dr Christopher JensenDr Christopher Jensen, Chief Operating Officer, Triple Helix Science20 Oct 2026

Areas of expertise

All areas →
Clinical GovernancePatient CareCross-Border CareHealth System TransformationModel of Care Design

Most asked

What is clinical governance in gene therapy and stem cell research?
Clinical governance is the system of standards, quality controls, consent processes and long-term participant follow-up that a clinical programme operates under. In gene therapy, regenerative medicine and stem cell science it carries further than in conventional drug work, because a genetic or cellular intervention is not withdrawn when dosing stops. Clinical governance is what makes a therapeutic protocol auditable by a regulator, an ethics committee or a sovereign health system.
What does a clinical governance expert actually do on a research programme?
A clinical governance expert writes the protocol a programme runs to, sets the consent language participants sign, defines how tissue, cells and participant data are handled and traced, qualifies each site before it opens, and fixes the follow-up schedule after dosing. Where a programme runs across more than one country, the same expert reconciles the differing national requirements into a single operating standard rather than letting each site interpret the protocol locally.
How is clinical governance judged on a programme?
Clinical governance is judged on whether the record can be produced on demand: every site running the current protocol version, consent traceable to each named participant, adverse events reported inside the stated window, and follow-up contact held over years rather than decaying after the dosing phase. Triple Helix Science reports completing a Phase 1 human trial showing reversal of dementia progression, and a result of that weight is only usable institutionally if the governance record behind it stands up to audit.
Is clinical governance the same as regulatory affairs?
No. Regulatory affairs manages the relationship with the regulator, which means submissions, dossiers, approvals and correspondence. Clinical governance determines what happens inside the clinic and the laboratory every day: who may consent a participant, how a cell product is released, what gets escalated and how fast. A programme can hold every approval it needs and still fail on governance, which is where patient harm and unusable data come from.
When does a research programme need clinical governance support?
A programme needs clinical governance in place before the first human dose, and again before it adds sites, crosses a border, or moves from trial to delivery inside a national health system. Purely preclinical work with no human participants does not need the full framework yet, though donor tissue provenance and consent still apply from the moment human material is used. Triple Helix Science works at the institutional level with governments, sovereign health systems, research universities and pharmaceutical organisations rather than with individual patients.

Contact for media

Reach Christopher directly for comment, background or an interview, on deadline or ahead of one.

Straight to the Triple Helix Science press team.